I’ve added a fun and helpful new feature on the right side bar of the blog in the form of a stem cell biotech stock ticker. The ticker is for some of the most widely held stem and cellular medicine companies. A sample screen shot is shown in this post. Quite a few stem cell-related […]
New Stem Cell Stock Ticker Read More »
Where do things stand with some players in the for-profit world of stem cell and cellular medicine companies? Here are a few brief news items with quick analysis. Mesoblast is dominating the news of late. Mesoblast reported good news from its Phase II safety trial for its mesenchymal progenitor cell (MPC) product in patients with
Stem Cell & Cell Med Industry Briefs Read More »
Over at the Harvard Law “Bill of Health” blog, Mary Ann Chirba and Alice A. Nobel posted a piece entitled “Our Bodies, Our Cells” a few days ago that has generated a lot of discussion about FDA regulation of stem cell interventions. Their piece really has two parts. In the first part they go through
My response to ‘Our Bodies, Our Cells’ Harvard post on deregulation Read More »
The Vatican Stem Cell Meeting 2013 has started. We are fortunate to have a guest blogger, John A. Carbona, CEO of BioLife Cell Bank, who is in attendance and kindly is giving us inside coverage of the meeting. Below is a guest blog from John on Day 1 of the meeting. We even have pictures.
Guest blog from inside Vatican Stem Cell Meeting by John Carbona: Day 1 Read More »
I recently did a Q&A interview with NeoStem CEO Dr. Robin Smith. I posted Part 1 of that interview a few days ago here. Now we have part two focused on VSEL, ES cells, and iPS cells. PK: I frequently have readers of my blog ask questions about VSEL. They seem puzzled and unsure of
Interview with NeoStem CEO Robin Smith Part 2: VSEL, ES cells, and iPS cells Read More »